Malaria investigational vaccine

Malaria Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Parasitic diseases
Malaria
 
Phase 2b
Matrix-M™ adjuvant
Therapeutic area
Parasitic diseases
Infectious disease
Malaria
Status
 
Phase 2b
Technology
Matrix-M™ adjuvant

About the candidate

R21* is a protein-based investigational vaccine developed by the University of Oxford, using our Matrix-M™ adjuvant technology.1 This investigational vaccine is specifically designed to help protect against malaria.

Why it matters

Malaria remains a significant global burden of disease,2 infecting nearly 230 million people worldwide in 2019 alone, with an estimated 409,000 deaths. New, effective vaccines are urgently needed to address this threat.1

R21 has been evaluated in safety and efficacy trials in both adults and children.

*Investigational vaccine created and trial sponsored by University of Oxford in collaboration with Serum Institute of India, with Matrix-M adjuvant.

  1. Matrix-M pipeline. 2021. Data on File.
  2. Malaria Fact Sheet. WHO. 1 Apr 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/malaria [Accessed 3 Sept 2021].